
ChemoCentryx (NASDAQ:CCXI) brought in sales totaling $2.31 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 81.68%, resulting in a loss of $40.53 million. ChemoCentryx collected $17.74 million in revenue during Q3, but reported earnings showed a $22.31 million loss.